Articles

Tuning in to the brain’s neural network

8 October 2021

The brain: how much don’t we know? Dr Jim Ross, Chief Technology Officer and Co-founder of Axion BioSystems, asks and discusses the answers to this question. Epilepsy, amyotrophic lateral sclerosis (ALS), Alzheimer’s — we hear these brain disease names all the time, but it feels like we never hear about effective treatments or cures. While medical advances are gradually helping researchers understand the brain and address neurological […]

Approaching bispecific antibody engineering

8 October 2021

Dr Michael Fiebig, Chief Scientific Officer, Absolute Antibody offers insight for those starting with a new bispecific antibody project  who may feel a little daunted by the wealth of formats out there. Over the past 10-plus years, there has been a dramatic rise in the exploitation of bispecific antibodies with over 100 currently in clinical […]

Connectivity and data standards – a precondition for successful digitalisation 

7 October 2021

  This paid-for whitepaper by The SiLA (Standardization in Lab Automation) consortium appeared in DDW Volume 22, Issue 4 – Fall 2021  R&D, manufacturing and contract research laboratories across many industries are investing in efforts to digitalise their processes and operations, with the goal of achieving end-to-end connectivity and automation. A common aim is to […]

AI in drug discovery: from Alzheimer’s to precision medicine 

29 September 2021

Artificial Intelligence (AI) is the simulation of human intelligence processes by machines, particularly computer systems, and finds itself at a climactic moment for its use within the drug discovery industry, especially as the world emerges from the Covid-19 pandemic.   “Artificial intelligence and machine learning continue to play important roles in drug discovery”, said Rupert Vessey, […]

Antibody-mediated therapies: meeting the challenges in R&D

28 September 2021

By Amanda Turner, Senior Product Manager for Custom Antibody Products at Bio-Rad and Laura Moriarty, Senior Marketing Manager at Bio-Rad The global market for therapeutic antibodies represents a huge and ever-expanding opportunity for pharmaceutical developers, with the market for monoclonal antibody therapies alone being estimated to reach $300 billion by 2025.1 However, the value of […]

Leveraging AI and Machine Learning for smarter clinical trial design 

27 September 2021

By Rafael Rosengarten, CEO of Genialis and Executive Member of the Board of Directors for the Alliance for Artificial Intelligence in Healthcare (AAIH)  How does a late-stage clinical trial fail when the preceding trials showed such promise? The likely reason is that the patients in the earlier trials were not representative of the larger population.    […]

Exclusive interview: BenevolentAI on the future of AI

22 September 2021

In what BenevolentAI considers a move that deepens its drug discovery and development expertise on its board, Dr John Orloff has been appointed as a Non-Executive Director. Dr Orloff joins the BenevolentAI board as it advances plans to scale its AI platform, partnerships and drug portfolio. DDW’s Megan Thomas speaks with Dr Orloff about his career and the future of […]

Building a pipeline of clinically-differentiated cancer therapies 

1 September 2021

As previously reported by DDW, Avacta Group has dosed the first patient in its Phase I multicentre trial evaluating AVA6000, a novel pro-drug of Doxorubicin and the company’s first therapeutic based on its pre|CISION technology. Megan Thomas speaks Dr Alastair Smith, Chief Executive Officer of Avacta Group, about this development.   MT: You previously commented that this study marks the transformation of Avacta Life Sciences into a […]

Optimising vaccine production through customisation

16 August 2021

An expert’s view by John Yoshi Shyu, Ph.D. Corning Life Sciences. Most vaccines are manufactured using technology devised fifty or more years ago, in manufacturing plants that are sometimes even older. The vaccine production process is continually refreshed by new tools and technologies, and that fast-paced innovation gives researchers numerous opportunities to adjust their processes […]

FDA vs EMA: biotechs & the challenges of international pharmacovigilance

12 August 2021

Biotechs involved in drug discovery have to navigate increasingly complex regulatory environments across borders. Experienced experts and non-executive advisors to Arriello, Eric Caugant in Paris and Judi Sills in New Jersey highlight the main differences between US and EU requirements, and advise on best preparations. Small biotech companies are commanding an increasingly prominent role in […]

« Previous
Next »

Join FREE today and become a member
of Drug Discovery World

Membership includes:

  • Full access to the website including free and gated premium content in news, articles, business, regulatory, cancer research, intelligence and more.
  • Unlimited App access: current and archived digital issues of DDW magazine with search functionality, special in App only content and links to the latest industry news and information.
  • Weekly e-newsletter, a round-up of the most interesting and pertinent industry news and developments.
  • Whitepapers, eBooks and information from trusted third parties.
Join For Free